COSCIENS Biopharma (CSCI)announced initiation of its Phase 2a clinical efficacy study of its flagship avenanthramides product being developed ...
Longeveron (LGVN) announced the publication in Nature Medicine of results from the CLEAR MIND Phase 2a clinical trial evaluating laromestrocel ...
Agomab Therapeutics NV (Agomab) has announced positive interim results from 44 patients completing treatment in the ongoing ...
Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of ...
Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug candidate, PN6047, in a pre-IND meeting ...
Longeveron Inc. announced positive results from its Phase 2a CLEAR MIND clinical trial of laromestrocel (Lomecel-Bâ„¢), a cellular therapy for mild Alzheimer's disease, published in Nature Medicine.
Sensorion (FR0012596468 - ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...
The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428).
today announced that patient dosing has been completed in its MUSIC-HFrEF Phase 1/2a clinical trial of the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback